DE69519463D1 - N-morpholino-n-nitrosaminoacetonitril-cyclodextrin-einschlussverbindungen - Google Patents

N-morpholino-n-nitrosaminoacetonitril-cyclodextrin-einschlussverbindungen

Info

Publication number
DE69519463D1
DE69519463D1 DE69519463T DE69519463T DE69519463D1 DE 69519463 D1 DE69519463 D1 DE 69519463D1 DE 69519463 T DE69519463 T DE 69519463T DE 69519463 T DE69519463 T DE 69519463T DE 69519463 D1 DE69519463 D1 DE 69519463D1
Authority
DE
Germany
Prior art keywords
sin
complexes
pct
ions
cyclodextrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69519463T
Other languages
English (en)
Other versions
DE69519463T2 (de
Inventor
Joseph Geczy
Andrasne Vikmon
Jozsef Szejtli
Lajos Szente
Julianna Szeman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Therabel Industries SA
Original Assignee
Therabel Industries SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therabel Industries SA filed Critical Therabel Industries SA
Application granted granted Critical
Publication of DE69519463D1 publication Critical patent/DE69519463D1/de
Publication of DE69519463T2 publication Critical patent/DE69519463T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
DE69519463T 1994-04-26 1995-04-25 N-morpholino-n-nitrosaminoacetonitril-cyclodextrin-einschlussverbindungen Expired - Lifetime DE69519463T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU9401183A HU218280B (en) 1994-04-26 1994-04-26 Cyclodextrin inclusion complexes containing sin-1a which are stable intheir solid state, process for their preparation and pharmaceutical compositions containing the comlexes
PCT/HU1995/000011 WO1995029172A1 (en) 1994-04-26 1995-04-25 N-morpholino-n-nitrosaminoacetonitril cyclodextrin inclusion complexes

Publications (2)

Publication Number Publication Date
DE69519463D1 true DE69519463D1 (de) 2000-12-28
DE69519463T2 DE69519463T2 (de) 2001-06-28

Family

ID=10985114

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69519463T Expired - Lifetime DE69519463T2 (de) 1994-04-26 1995-04-25 N-morpholino-n-nitrosaminoacetonitril-cyclodextrin-einschlussverbindungen

Country Status (32)

Country Link
US (1) US5698535A (de)
EP (1) EP0705255B1 (de)
JP (1) JP3434828B2 (de)
KR (1) KR960703404A (de)
CN (1) CN1060164C (de)
AT (1) ATE197708T1 (de)
AU (1) AU694219B2 (de)
BG (1) BG61974B1 (de)
BR (1) BR9506155A (de)
CA (1) CA2163539C (de)
CZ (1) CZ316395A3 (de)
DE (1) DE69519463T2 (de)
DK (1) DK0705255T3 (de)
ES (1) ES2153897T3 (de)
FI (1) FI956156A (de)
GR (1) GR3035356T3 (de)
HR (1) HRP950249A2 (de)
HU (1) HU218280B (de)
IL (1) IL113491A (de)
LT (1) LT4167B (de)
LV (1) LV11543B (de)
MD (1) MD1419G2 (de)
NO (1) NO311030B1 (de)
NZ (1) NZ285149A (de)
PL (1) PL312183A1 (de)
PT (1) PT705255E (de)
RO (1) RO114449B1 (de)
RU (1) RU2136698C1 (de)
SI (1) SI0705255T1 (de)
SK (1) SK155195A3 (de)
WO (1) WO1995029172A1 (de)
YU (1) YU25995A (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
DE60032388T2 (de) * 1999-11-12 2008-01-10 Frères Roquette Kristalline mischungen aus teilmethylethern des beta-cyclodextrins und verwandten verbindungen
FR2805462B1 (fr) * 2000-02-24 2003-08-15 Therabel Res Nouvelle forme galenique orale a liberation prolongee de la molsidomine
TWI321054B (en) * 2000-12-19 2010-03-01 California Inst Of Techn Compositions containing inclusion complexes
EP1219306A1 (de) 2000-12-29 2002-07-03 Nicox S.A. Zyklodextrin und NO-abgebende Arzneimittlen enthaltende Zusammensetzungen
CA2497792C (en) 2002-09-06 2014-08-05 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
JP4602085B2 (ja) * 2002-10-09 2010-12-22 セルリアン・ファーマ・インコーポレイテッド シクロデキストリンを基材とした物質、組成物及びこれらと関連する用途
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
AU2010321533A1 (en) * 2009-11-23 2012-05-31 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
US20140094432A1 (en) 2012-10-02 2014-04-03 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
CA3078625C (en) 2017-10-09 2023-01-17 Terumo Bct Biotechnologies, Llc Lyophilization container and method of using same
EP3938741B1 (de) 2019-03-14 2024-05-01 Terumo BCT Biotechnologies, LLC Lyophilisierungsbehälterfüllvorrichtung, system und verfahren zur verwendung
CN116249522A (zh) * 2020-07-20 2023-06-09 深圳迈瑞生物医疗电子股份有限公司 一种组合物的血小板解聚用途、解聚试剂及解聚方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208233A (en) * 1989-09-15 1993-05-04 The United States Of America As Represented By The Department Of Health And Human Services Anti-hypertensive compositions of secondary amine-nitric oxide adducts and use thereof
US5039705A (en) * 1989-09-15 1991-08-13 The United States Of America As Represented By The Department Of Health And Human Services Anti-hypertensive compositions of secondary amine-nitric oxide adducts and use thereof
US5212204A (en) * 1989-10-18 1993-05-18 The United States Of America As Represented By The Department Of Health And Human Services Antihypertensive compositions and use thereof
HU211648A9 (en) * 1990-03-28 1995-12-28 Chinoin Gyogyszer Es Vegyeszet Inclusion complexes of 3-morpholino-sydnonimine or its salts or its tautomer isomer, process for the preparation thereof, and pharmaceutical compositions containing the same
EP0605622B1 (de) * 1991-09-24 1997-11-12 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Sauerstoff-substituierte derivate von nucleophil-stickstoffoxid-addukten und ihre verwendung als stickstoffoxid-donor-prodrugs
US5389675A (en) * 1992-03-27 1995-02-14 The United States Of America As Represented By The Department Of Health And Human Services Mixed ligand metal complexes of nitric oxide-nucleophile adducts useful as cardiovascular agents

Also Published As

Publication number Publication date
AU694219B2 (en) 1998-07-16
CZ316395A3 (en) 1996-05-15
FI956156A0 (fi) 1995-12-20
SI0705255T1 (en) 2001-04-30
GR3035356T3 (en) 2001-05-31
US5698535A (en) 1997-12-16
CA2163539C (en) 2003-04-01
LV11543B (en) 1996-12-20
JP3434828B2 (ja) 2003-08-11
MD1419G2 (ro) 2000-11-30
LV11543A (lv) 1996-10-20
CN1060164C (zh) 2001-01-03
EP0705255B1 (de) 2000-11-22
IL113491A0 (en) 1995-07-31
DE69519463T2 (de) 2001-06-28
RU2136698C1 (ru) 1999-09-10
MD1419F2 (en) 2000-02-29
HUT70750A (en) 1995-10-30
AU2415995A (en) 1995-11-16
EP0705255A1 (de) 1996-04-10
JPH09503546A (ja) 1997-04-08
RO114449B1 (ro) 1999-04-30
PT705255E (pt) 2001-05-31
WO1995029172A1 (en) 1995-11-02
NZ285149A (en) 1998-06-26
BG100313A (bg) 1996-07-31
FI956156A (fi) 1995-12-20
KR960703404A (ko) 1996-08-17
CA2163539A1 (en) 1995-11-02
MD950440A (en) 1997-10-31
ES2153897T3 (es) 2001-03-16
PL312183A1 (en) 1996-04-01
IL113491A (en) 2002-03-10
HRP950249A2 (en) 1997-10-31
NO955283L (no) 1995-12-22
BG61974B1 (bg) 1998-11-30
LT4167B (en) 1997-06-25
DK0705255T3 (da) 2000-12-11
NO955283D0 (no) 1995-12-22
NO311030B1 (no) 2001-10-01
ATE197708T1 (de) 2000-12-15
BR9506155A (pt) 1996-04-16
YU25995A (sh) 1998-08-14
LT95133A (en) 1996-10-25
HU9401183D0 (en) 1994-07-28
HU218280B (en) 2000-07-28
SK155195A3 (en) 1997-05-07
CN1128028A (zh) 1996-07-31

Similar Documents

Publication Publication Date Title
DE69519463T2 (de) N-morpholino-n-nitrosaminoacetonitril-cyclodextrin-einschlussverbindungen
Weil‐Malherbe Activators and inhibitors of brain glutaminase
DE3771362D1 (de) Verfahren zur herstellung von sehr reinem dermatansulfat und pharmazeutische zusammensetzungen, welche dieses enthalten.
US5466846A (en) Process for preparation of stable aqueous solutions of zirconium chelates
RU96100760A (ru) Новые комплексы включения sin-1a и циклодекстрина
BR0114251A (pt) Carbonato de sódio granulado obtido através de granulação por pulverização em leito fluido e um processo para sua produção
Tagaki et al. The syntheses and hydrolyses of p-substituted phenyl phosphosulfates
JPS5935B2 (ja) ウロキナ−ゼの精製法
JP3081016B2 (ja) 結晶性チオニコチンアミド−アデニンジヌクレオ チド燐酸カリウム塩及びその製造法
GB1270448A (en) Heavy metal complexes of cephalosporin c and process for the isolation of cephalosporin c in the form of such complexes
SU1353727A1 (ru) Способ получени кристаллического двойного фосфата титана и магни общей формулы @ -TI MG(РО @ ) @ 3Н @ О
SU473675A1 (ru) Способ получени двойного соединени фосфата уранила с одновалентным катионом
JP3228831B2 (ja) カルシウムイオンの溶出が抑制されたリン酸水素カルシウムの製造方法
KR950003168A (ko) 산화제이철의 제조방법
JPS61227507A (ja) 葉の成長剤乾燥組成物
KR970073342A (ko) 은(Ag) 함유 무기 항균제의 제조방법
JPH0959165A (ja) 安定化ポリヨウ化物製剤の製造法
JPH0280311A (ja) 水酸アパタイトの湿式合成法
JPS6118796A (ja) アデノシン５′―三リン酸の製造方法
TH10349EX (th) กรรมวิธีสำหรับเตรียมผลิตภัณฑ์ออกซิไดส์ เซลลูโลส ที่ทำให้เป็นกลางและวิธีการใช้
JPS63229057A (ja) 安定な第一鉄化合物水溶液
JPH0653753B2 (ja) ヘキソースリン酸金属塩及びその製造法

Legal Events

Date Code Title Description
8364 No opposition during term of opposition